{"id":394361,"date":"2026-04-22T16:10:37","date_gmt":"2026-04-22T14:10:37","guid":{"rendered":"https:\/\/ga-p.com\/?post_type=publicacion&p=394361"},"modified":"2026-04-22T16:10:40","modified_gmt":"2026-04-22T14:10:40","slug":"the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive","status":"publish","type":"publicacion","link":"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/","title":{"rendered":"The new obligation to supply medicines at the request of Member States: analysis of Article56a of the Medicines Directive"},"content":{"rendered":"
\n
\n
\n
\n
\n\n

Article56a of the European Union\u2019s new Medicines Directive introduces a mechanism that allows Member States to require marketing authorisation holders to supply authorised medicines within their territory to meet the needs of their patients. In the event of non-compliance three years after the request, the holder may lose market protection in that Member State, thereby allowing the entry of generic and biosimilar medicines. However, exceptions are provided for in cases of exceptional and unforeseeable circumstances beyond the holder\u2019s control, as well as safeguards to prevent the loss of protection in one Member State from being used to circumvent the system in other protected markets.<\/p>\n\n\n\n

\n
\n \"icon\"\n

Download document<\/p>\n<\/div>\n <\/div>\n

\n View document \"icon\"\n <\/a>\n <\/div>\n<\/div>\n\n<\/div>\n<\/div>\n\n\n
\n
\n\n\n
\n\n
\n
\n\n
\n
Autor\/s<\/div>\n
\n

\n <\/span>\n Irene Ferna\u0301ndez Puyol<\/a>\n – Partner<\/span>\n <\/p>\n <\/div>\n <\/div>\n \n \n

\n
Category<\/div>\n

\n <\/span>\n Analysis<\/span>\n <\/p>\n <\/div>\n \n <\/div>\n<\/div>\n\n<\/div>\n<\/div>\n\n<\/div>\n\n <\/div>\n\n<\/div>\n\n\n

\n
\n
\n
\n
\n\n
\n\n\n
\n See previous \"icon\"\n <\/a>\n See next \"icon\"\n <\/a>\n <\/div>\n <\/div>\n<\/div>\n<\/div>\n\n\n
\n
<\/div>\n<\/div>\n\n<\/div>\n\n <\/div>\n\n<\/div>\n\n\n\n\n
\n
\n
\n
\n
<\/div>\n <\/div>\n <\/div>\n
\n \n
\n \n
\n \"Irene <\/div>\n <\/a>\n
\n \n
Irene Ferna\u0301ndez Puyol<\/div>\n <\/a>\n
Partner<\/div>\n
\n \"email\"\n\n ifernandez@ga-p.com<\/a>\n <\/div>\n
\n \n
\n Public Law and Regulated Sectors<\/a>\n <\/div>\n <\/div>\n
\n \n Madrid<\/a>\n <\/div>\n
\n \"icon\"\n\n (+34) 91 582 91 00<\/a>\n <\/div>\n <\/div>\n <\/div>\n\n \n
\n \"icon\"\n \"icon\"\n \n <\/div>\n <\/a>\n <\/div>\n <\/div>\n
\n
\n
\n
\n \n
\n \n
\n \"Irene <\/div>\n <\/a>\n
\n \n
Irene Ferna\u0301ndez Puyol<\/div>\n <\/a>\n
Partner<\/div>\n
\n \"email\"\n\n ifernandez@ga-p.com<\/a>\n <\/div>\n
\n \n
\n Public Law and Regulated Sectors<\/a>\n <\/div>\n <\/div>\n
\n \n Madrid<\/a>\n <\/div>\n
\n \"icon\"\n\n (+34) 91 582 91 00<\/a>\n <\/div>\n <\/div>\n <\/div>\n\n \n
\n \"icon\"\n \"icon\"\n \n <\/div>\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
<\/div>\n
\n
\n
\"icon\"<\/div>\n
\"icon\"<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Article 56a of the European Union\u2019s new Medicines Directive introduces a mechanism that allows Member States to require marketing authorisation holders to supply authorised medicines within their territory to meet the needs of their patients. In the event of non-compliance three years after the request, the holder may lose market protection in that Member State, thereby allowing the entry of generic and biosimilar medicines. However, exceptions are provided for in cases of exceptional and unforeseeable circumstances beyond the holder\u2019s control, as well as safeguards to prevent the loss of protection in one Member State from being used to circumvent the system in other protected markets.<\/p>\n","protected":false},"featured_media":390686,"template":"","publicacion_categoria":[126],"class_list":["post-394361","publicacion","type-publicacion","status-publish","has-post-thumbnail","hentry","publicacion_categoria-analysis-en"],"acf":[],"yoast_head":"\nThe new obligation to supply medicines at the request of Member States: analysis of Article56a of the Medicines Directive - Despacho de abogados G\u00f3mez-Acebo y Pombo<\/title>\n<meta name=\"description\" content=\"Article 56a of the European Union\u2019s new Medicines Directive introduces a mechanism that allows Member States to require marketing authorisation holders to supply authorised medicines within their territory to meet the needs of their patients. In the event of non-compliance three years after the request, the holder may lose market protection in that Member State, thereby allowing the entry of generic and biosimilar medicines. However, exceptions are provided for in cases of exceptional and unforeseeable circumstances beyond the holder\u2019s control, as well as safeguards to prevent the loss of protection in one Member State from being used to circumvent the system in other protected markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The new obligation to supply medicines at the request of Member States: analysis of Article56a of the Medicines Directive - Despacho de abogados G\u00f3mez-Acebo y Pombo\" \/>\n<meta property=\"og:description\" content=\"Article 56a of the European Union\u2019s new Medicines Directive introduces a mechanism that allows Member States to require marketing authorisation holders to supply authorised medicines within their territory to meet the needs of their patients. In the event of non-compliance three years after the request, the holder may lose market protection in that Member State, thereby allowing the entry of generic and biosimilar medicines. However, exceptions are provided for in cases of exceptional and unforeseeable circumstances beyond the holder\u2019s control, as well as safeguards to prevent the loss of protection in one Member State from being used to circumvent the system in other protected markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/\" \/>\n<meta property=\"og:site_name\" content=\"Despacho de abogados G\u00f3mez-Acebo y Pombo\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-22T14:10:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ga-p.com\/wp-content\/uploads\/2026\/03\/Analysis-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1308\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\\\/\",\"url\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\\\/\",\"name\":\"The new obligation to supply medicines at the request of Member States: analysis of Article56a of the Medicines Directive - Despacho de abogados G\u00f3mez-Acebo y Pombo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ga-p.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Analysis-1.jpg\",\"datePublished\":\"2026-04-22T14:10:37+00:00\",\"dateModified\":\"2026-04-22T14:10:40+00:00\",\"description\":\"Article 56a of the European Union\u2019s new Medicines Directive introduces a mechanism that allows Member States to require marketing authorisation holders to supply authorised medicines within their territory to meet the needs of their patients. In the event of non-compliance three years after the request, the holder may lose market protection in that Member State, thereby allowing the entry of generic and biosimilar medicines. However, exceptions are provided for in cases of exceptional and unforeseeable circumstances beyond the holder\u2019s control, as well as safeguards to prevent the loss of protection in one Member State from being used to circumvent the system in other protected markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ga-p.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Analysis-1.jpg\",\"contentUrl\":\"https:\\\/\\\/ga-p.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Analysis-1.jpg\",\"width\":2500,\"height\":1308},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ga-p.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The new obligation to supply medicines at the request of Member States: analysis of Article56a of the Medicines Directive\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/ga-p.com\\\/en\\\/\",\"name\":\"Despacho de abogados G\u00f3mez-Acebo & Pombo\",\"description\":\"G\u00f3mez-Acebo y Pombo es una firma de abogados independiente, con experiencia internacional, especializada en todas las \u00e1reas del derecho de los negocio.\",\"publisher\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ga-p.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#organization\",\"name\":\"Despacho de abogados G\u00f3mez-Acebo & Pombo\",\"url\":\"https:\\\/\\\/ga-p.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ga-p.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo-1-1.svg\",\"contentUrl\":\"https:\\\/\\\/ga-p.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo-1-1.svg\",\"caption\":\"Despacho de abogados G\u00f3mez-Acebo & Pombo\"},\"image\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The new obligation to supply medicines at the request of Member States: analysis of Article56a of the Medicines Directive - Despacho de abogados G\u00f3mez-Acebo y Pombo","description":"Article 56a of the European Union\u2019s new Medicines Directive introduces a mechanism that allows Member States to require marketing authorisation holders to supply authorised medicines within their territory to meet the needs of their patients. In the event of non-compliance three years after the request, the holder may lose market protection in that Member State, thereby allowing the entry of generic and biosimilar medicines. However, exceptions are provided for in cases of exceptional and unforeseeable circumstances beyond the holder\u2019s control, as well as safeguards to prevent the loss of protection in one Member State from being used to circumvent the system in other protected markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/","og_locale":"en_US","og_type":"article","og_title":"The new obligation to supply medicines at the request of Member States: analysis of Article56a of the Medicines Directive - Despacho de abogados G\u00f3mez-Acebo y Pombo","og_description":"Article 56a of the European Union\u2019s new Medicines Directive introduces a mechanism that allows Member States to require marketing authorisation holders to supply authorised medicines within their territory to meet the needs of their patients. In the event of non-compliance three years after the request, the holder may lose market protection in that Member State, thereby allowing the entry of generic and biosimilar medicines. However, exceptions are provided for in cases of exceptional and unforeseeable circumstances beyond the holder\u2019s control, as well as safeguards to prevent the loss of protection in one Member State from being used to circumvent the system in other protected markets.","og_url":"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/","og_site_name":"Despacho de abogados G\u00f3mez-Acebo y Pombo","article_modified_time":"2026-04-22T14:10:40+00:00","og_image":[{"width":2500,"height":1308,"url":"https:\/\/ga-p.com\/wp-content\/uploads\/2026\/03\/Analysis-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/","url":"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/","name":"The new obligation to supply medicines at the request of Member States: analysis of Article56a of the Medicines Directive - Despacho de abogados G\u00f3mez-Acebo y Pombo","isPartOf":{"@id":"https:\/\/ga-p.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/#primaryimage"},"image":{"@id":"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/#primaryimage"},"thumbnailUrl":"https:\/\/ga-p.com\/wp-content\/uploads\/2026\/03\/Analysis-1.jpg","datePublished":"2026-04-22T14:10:37+00:00","dateModified":"2026-04-22T14:10:40+00:00","description":"Article 56a of the European Union\u2019s new Medicines Directive introduces a mechanism that allows Member States to require marketing authorisation holders to supply authorised medicines within their territory to meet the needs of their patients. In the event of non-compliance three years after the request, the holder may lose market protection in that Member State, thereby allowing the entry of generic and biosimilar medicines. However, exceptions are provided for in cases of exceptional and unforeseeable circumstances beyond the holder\u2019s control, as well as safeguards to prevent the loss of protection in one Member State from being used to circumvent the system in other protected markets.","breadcrumb":{"@id":"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/#primaryimage","url":"https:\/\/ga-p.com\/wp-content\/uploads\/2026\/03\/Analysis-1.jpg","contentUrl":"https:\/\/ga-p.com\/wp-content\/uploads\/2026\/03\/Analysis-1.jpg","width":2500,"height":1308},{"@type":"BreadcrumbList","@id":"https:\/\/ga-p.com\/en\/publications\/the-new-obligation-to-supply-medicines-at-the-request-of-member-states-analysis-of-article56a-of-the-medicines-directive\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ga-p.com\/en\/"},{"@type":"ListItem","position":2,"name":"The new obligation to supply medicines at the request of Member States: analysis of Article56a of the Medicines Directive"}]},{"@type":"WebSite","@id":"https:\/\/ga-p.com\/en\/#website","url":"https:\/\/ga-p.com\/en\/","name":"Despacho de abogados G\u00f3mez-Acebo & Pombo","description":"G\u00f3mez-Acebo y Pombo es una firma de abogados independiente, con experiencia internacional, especializada en todas las \u00e1reas del derecho de los negocio.","publisher":{"@id":"https:\/\/ga-p.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ga-p.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ga-p.com\/en\/#organization","name":"Despacho de abogados G\u00f3mez-Acebo & Pombo","url":"https:\/\/ga-p.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ga-p.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ga-p.com\/wp-content\/uploads\/2024\/09\/Logo-1-1.svg","contentUrl":"https:\/\/ga-p.com\/wp-content\/uploads\/2024\/09\/Logo-1-1.svg","caption":"Despacho de abogados G\u00f3mez-Acebo & Pombo"},"image":{"@id":"https:\/\/ga-p.com\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/publicacion\/394361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/publicacion"}],"about":[{"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/types\/publicacion"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/media\/390686"}],"wp:attachment":[{"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/media?parent=394361"}],"wp:term":[{"taxonomy":"publicacion_categoria","embeddable":true,"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/publicacion_categoria?post=394361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}